[go: up one dir, main page]

AR111840A1 - Polipéptidos que antagonizan la señalización wnt en células tumorales - Google Patents

Polipéptidos que antagonizan la señalización wnt en células tumorales

Info

Publication number
AR111840A1
AR111840A1 ARP180101427A ARP180101427A AR111840A1 AR 111840 A1 AR111840 A1 AR 111840A1 AR P180101427 A ARP180101427 A AR P180101427A AR P180101427 A ARP180101427 A AR P180101427A AR 111840 A1 AR111840 A1 AR 111840A1
Authority
AR
Argentina
Prior art keywords
polypeptides
wnt signaling
tumor cells
methods
antagonize wnt
Prior art date
Application number
ARP180101427A
Other languages
English (en)
Inventor
Beatrijs Strubbe
Stephanie Staelens
Karen Cromie
Marie Buyse
- Kuenkele Klaus Ange
- Zinzalla Vittoria Peter
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR111840A1 publication Critical patent/AR111840A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Polipéptidos de fijación a LRP5 y, más específicamente, constructos de dominio variable único de inmunoglobulina de fijación a LRP5, que pueden inhibir las vías de señalización Wnt. Secuencias específicas de estos polipéptidos, métodos para su producción y métodos para usarlos, que incluyen métodos para el tratamiento de enfermedades, tales como cáncer.
ARP180101427A 2017-05-31 2018-05-30 Polipéptidos que antagonizan la señalización wnt en células tumorales AR111840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31

Publications (1)

Publication Number Publication Date
AR111840A1 true AR111840A1 (es) 2019-08-21

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101427A AR111840A1 (es) 2017-05-31 2018-05-30 Polipéptidos que antagonizan la señalización wnt en células tumorales

Country Status (25)

Country Link
US (3) US11033636B2 (es)
EP (1) EP3630816B1 (es)
JP (1) JP7216024B2 (es)
KR (1) KR102717656B1 (es)
CN (1) CN110637030B (es)
AR (1) AR111840A1 (es)
AU (1) AU2018276409B2 (es)
BR (1) BR112019022729A2 (es)
CA (1) CA3060401A1 (es)
CL (1) CL2019003419A1 (es)
CO (1) CO2019012329A2 (es)
EA (1) EA201992808A1 (es)
ES (1) ES2979194T3 (es)
HU (1) HUE067691T2 (es)
IL (1) IL270854B2 (es)
MA (1) MA48760A (es)
MX (1) MX2019014331A (es)
MY (1) MY200744A (es)
PE (1) PE20200610A1 (es)
PH (1) PH12019502602A1 (es)
PL (1) PL3630816T3 (es)
TW (1) TWI887192B (es)
UA (1) UA125761C2 (es)
WO (1) WO2018220080A1 (es)
ZA (1) ZA201906610B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110637030B (zh) * 2017-05-31 2024-06-11 勃林格殷格翰国际有限公司 拮抗肿瘤细胞中Wnt信号传导的多肽
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
JP7330977B2 (ja) 2017-12-19 2023-08-22 スロゼン オペレーティング， インコーポレイテッド Ｗｎｔサロゲート分子及びその使用
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
WO2019126399A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP3924381A4 (en) * 2019-02-11 2023-07-26 Surrozen Operating, Inc. MODULATION OF WNT SIGNALING IN EYE DISEASES
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法
AU2020329092A1 (en) * 2019-08-14 2022-03-31 Antlera Therapeutics Inc. Antibodies that bind to LRP5 proteins and methods of use
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023243759A1 (ko) * 2021-07-13 2023-12-21 인제대학교 산학협력단 Neurl 유전자, 이를 포함하는 발현벡터 또는 neurl 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
EP4384552A4 (en) * 2021-08-10 2025-07-09 Heat Biologics Inc GENERATION AND CHARACTERIZATION OF NOVEL TIM-4 BINDING AGENTS
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU733722B2 (en) 1997-04-15 2001-05-24 Merck Sharp & Dohme Corp. Novel LDL-receptor
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002342734B2 (en) 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
KR101103218B1 (ko) 2002-11-08 2012-01-05 아블린쓰 엔.브이. 종양 괴사 인자-알파에 대한 단일 도메인 항체 및 그 용도
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
MX363423B (es) 2005-05-18 2019-03-22 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
WO2007027509A2 (en) 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
CA2791991A1 (en) * 2010-03-24 2011-09-29 Genentech, Inc. Anti-lrp6 antibodies
EA201291181A1 (ru) 2010-05-06 2013-05-30 Новартис Аг Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
PE20130207A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
CA2825211A1 (en) * 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Standford Junior University Wnt compositions and methods of use thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
PH12022550311A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR102143506B1 (ko) 2011-08-17 2020-08-12 글락소 그룹 리미티드 변형된 단백질 및 펩티드
AR088633A1 (es) 2011-11-04 2014-06-25 Novartis Ag Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6)
IN2014DN05885A (es) * 2012-01-18 2015-06-05 Hoffmann La Roche
JP7046804B2 (ja) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
US10597449B2 (en) * 2015-12-04 2020-03-24 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
CN110637030B (zh) * 2017-05-31 2024-06-11 勃林格殷格翰国际有限公司 拮抗肿瘤细胞中Wnt信号传导的多肽
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法

Also Published As

Publication number Publication date
JP7216024B2 (ja) 2023-01-31
US11033636B2 (en) 2021-06-15
US20180344868A1 (en) 2018-12-06
CN110637030B (zh) 2024-06-11
CL2019003419A1 (es) 2020-03-27
ZA201906610B (en) 2025-12-17
UA125761C2 (uk) 2022-06-01
IL270854B2 (en) 2023-02-01
BR112019022729A2 (pt) 2020-05-19
US12285493B2 (en) 2025-04-29
ES2979194T3 (es) 2024-09-24
EP3630816B1 (en) 2024-03-20
CN110637030A (zh) 2019-12-31
PH12019502602A1 (en) 2020-06-08
MY200744A (en) 2024-01-13
CO2019012329A2 (es) 2020-01-17
IL270854B (en) 2022-10-01
TW201906858A (zh) 2019-02-16
PE20200610A1 (es) 2020-03-10
KR102717656B1 (ko) 2024-10-14
US20250345448A1 (en) 2025-11-13
EP3630816C0 (en) 2024-03-20
TWI887192B (zh) 2025-06-21
MX2019014331A (es) 2020-01-27
KR20200011933A (ko) 2020-02-04
JP2020521478A (ja) 2020-07-27
MA48760A (fr) 2020-04-08
WO2018220080A1 (en) 2018-12-06
CA3060401A1 (en) 2018-12-06
US20220362393A1 (en) 2022-11-17
EP3630816A1 (en) 2020-04-08
PL3630816T3 (pl) 2024-08-05
IL270854A (en) 2020-01-30
AU2018276409B2 (en) 2025-02-27
HUE067691T2 (hu) 2024-11-28
EA201992808A1 (ru) 2020-05-14
AU2018276409A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
AR111840A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
CO2018005680A2 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
AR113862A1 (es) Anticuerpos anti-cd47 y sus usos para tratar cáncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX373323B (es) Procesos de siembra en serie y usos de los mismos.
CO2017004314A2 (es) Compuestos anti-tnf
UY37018A (es) Inhibidores bicíclicos de pad4
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX385138B (es) Inmunomoduladores de aminoacilindazol para el tratamiento de enfermedades autoinmunes.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
IL259486A (en) Agents for the treatment of diseases associated with undesired cell proliferation
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний